Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Apex Clinical Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$2,053,319

360 payments

Through program year 2025, Apex Clinical Research Center LLC is reported as receiving $2,053,319 in research payments, across 360 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $999,309 170
2024 Research $920,298 105
2023 Research $87,149 73
2022 Research $46,563 12

Breakdown

Who paid Research payments · program years 2022–2025
  1. AbbVie, Inc. $729,076 109 payments
  2. Amgen Inc. $501,965 12 payments
  3. Sanofi US Services Inc. $335,393 67 payments
  4. Pfizer Inc. $147,239 27 payments
  5. Janssen Research & Development, LLC $109,922 15 payments
  6. E.R. Squibb & Sons, L.L.C. $83,873 2 payments
  7. Dermavant Sciences, Inc. $68,551 113 payments
  8. Sun Pharmaceutical Industries Inc. $42,300 7 payments
  9. Almirall LLC $35,000 8 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $257,660 31 payments
  2. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $254,838 35 payments
  3. OUTPOST Clinical Home Use Study $221,247 3 payments
  4. A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata $133,553 36 payments
  5. ASCEND P3 AD Extension $121,089 2 payments
  6. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $109,922 15 payments
  7. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $106,101 21 payments
  8. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $103,136 17 payments
  9. VOYAGER P3 AD Vaccine Study $92,428 2 payments
  10. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $68,704 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record